{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-138138","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2025-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.971407+00:00","generated_at":"2026-05-19T15:42:53.220521+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Recursion cuts workforce ~20%, extends cash runway to Q4 2027; $11M severance charges","bullets":["Workforce reduction of ~20%; expects ~$11M in severance and related costs in 2025.","Cash runway now projected into Q4 2027; cash burn guidance <$450M in 2025, <$390M in 2026.","Expects Q2 2025 cash above $500M; includes $28M R&D tax credit and >$100M potential milestone inflows by end 2026.","Reduction part of streamlined operating strategy and post-integration transitions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-138138","json":"https://secwatch.observer/filing/0001193125-25-138138.json","markdown":"https://secwatch.observer/filing/0001193125-25-138138.md","text":"https://secwatch.observer/filing/0001193125-25-138138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000119312525138138/0001193125-25-138138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000119312525138138/d80288d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T15:42:53.220521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ab723ce50dcb900ce70f0d88f74ea59a22aa8ca","claim":"RECURSION PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $11 million (approximately 20%).","evidence_excerpt":"into the fourth quarter of 2027. These changes are expected to result in a workforce reduction of approximately 20%. The Company estimates that it will incur approximately $11 million in charges in connection with the workforce reduction, consisting of severance payments, employee benefits, and related costs, substantially all of which the Company expects to","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000119312525138138/0001193125-25-138138-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $11 million"},{"label":"Headcount","value":"approximately 20%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}